GHTF (Global Harmonisation Task Force) clinical evidence group sets clear agenda
This article was originally published in Clinica
The inaugural meeting of the new study group 5 on clinical evidence set up within the Global Harmonisation Task Force agreed its agenda for the year at its meeting on January 17-18. Chaired by Graeme Harris, chief clinical adviser at the Office of Devices, Blood and Tissues, of Australia's Therapeutics Goods Administration, the members of the group reached a consensus on how to proceed and share out information gathering and document drafting roles.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.